NCIC CLINICAL TRIALS GROUP

LOCALIZED PROSTATE

GU DISEASE ORIENTED GROUP MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

SATURDAY MAY 2ND, 2015, 7:00 AM – 8:00 AM

CO-CHAIRS: A. LOBLAW & N. FLESHNER
SENIOR INVESTIGATOR: WENDY PARULEKAR
STUDY COORDINATOR: ALEXANDER MONTENEGRO

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with localized prostate cancer in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to localized prostate cancer.
- To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to localized prostate cancer.

7:00 am    Welcome
            A. Loblaw & N. Fleshner

Ongoing studies:
7:05 am    PR.15 and follow-up study: Phase III study of HDR brachytherapy in intermediate risk CaP
            E. Vigneault/ A. Loblaw

Study Proposal Updates
7:15 am    Time Combination of metformin with radical radiotherapy for localized prostate cancer.
            T. Tsakiridis

7:25 am    Randomized phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localized, prostate cancer.
            ENZARAD (ANZUP)
            T. Niazi/M. Stockler

New studies/concepts/proposals developments
7:40 am    Ligand trial
            R. Hamilton

7:50 am    PACE – SBRT vs IMRT RCT
            A. Loblaw
            on behalf of W. Chu

8:00 am    Meeting Adjourned